Benefits of alnuctamab in the treatment of R/R multiple myeloma Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the advantages of the alnuctamab (formerly CC-93269), a novel BCMAxCD3 bispecific antibody, in the treatment of patients with relapsed/refractory (R/R) disease. Dr Cerchione explains that […]

Read More

The Multiple Myeloma Research Foundation – The Future The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure.

Read More